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ABSTRACT
The p53 family is known as a family of transcription
factors with functions in tumor suppression and
development. Whereas the central DNA-binding
domain is highly conserved among the three
family members p53, p63 and p73, the C-terminal
domains (CTDs) are diverse and subject to alter-
native splicing and post-translational modification.
Here we demonstrate that the CTDs strongly
influence DNA binding and transcriptional activity:
while p53 and the p73 isoform p73c have basic
CTDs and form weak sequence-specific protein–
DNA complexes, the major p73 isoforms have
neutral CTDs and bind DNA strongly. A basic CTD
has been previously shown to enable sliding along
the DNA backbone and to facilitate the search for
binding sites in the complex genome. Our experi-
ments, however, reveal that a basic CTD also
reduces protein–DNA complex stability, intranuc-
lear mobility, promoter occupancy in vivo, target
gene activation and induction of cell cycle arrest or
apoptosis. A basic CTD therefore provides both
positive and negative regulatory functions presum-
ably to enable rapid switching of protein activity in
response to stress. The different DNA-binding
characteristics of the p53 family members could
therefore reflect their predominant role in the
cellular stress response (p53) or developmental
processes (p73).
INTRODUCTION
The tumor suppressor p53 is known as ‘the guardian of
the genome’ owing to its ability to integrate many signals
that control life or death (1–3). Activated by various types
of cellular stress, including DNA damage and oncogenic
stress, p53 initiates transcriptional programs that ulti-
mately arrest proliferation and prevent the generation of
genetically altered cells. The spectrum of p53-based cell
fate decisions ranges from a transient cell-cycle arrest
enabling damage repair to an irreversible block of
proliferation through the induction of senescence, diﬀer-
entiation or apoptosis (1). This central role of p53 in cell
fate control is underlined by its frequent inactivation in
human cancer with an estimated 50% of malignancies
harboring a mutated p53 locus (2).
The p53 protein contains the classical features of
a sequence-speciﬁc transcriptional activator, including
an aminoterminal transactivation domain, a sequence-
speciﬁc DNA binding ‘core’ domain in the center of the
protein, and a tetramerization domain C-terminal to the
core. In addition, the extreme C-terminus of the p53
protein contains an arginine- and lysine-rich basic domain
which was shown to function as an autonomous sequence-
nonspeciﬁc nucleic acid binding region (4,5). Initial studies
suggested that the C-terminal domain (CTD) is a negative
autoregulator of sequence-speciﬁc DNA binding as
truncation of the entire CTD in p5330, replacement of
the CTD by alternative splicing, or blocking of the
CTD by antibodies and post-translational modiﬁcations
resulted in increased binding to short oligonucleotides
containing p53 binding sites (6–10). Based on these
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undergo a modiﬁcation-induced allosteric conformational
shift that enables the core domain to bind to p53 response
elements.
This allosteric model, however, was challenged by a
number of recent ﬁndings: NMR analysis demonstrated
that full-length and CTD-deleted mutants of p53 have
essentially similar structures (11). Furthermore, although
acetylation appears to increase p53 binding to short
double-stranded DNA fragments, it does not aﬀect the
ability of p53 to bind to its speciﬁc response element in the
context of chromatin or long DNA molecules (12).
Similarly, quantitative chromatin immunoprecipitation
failed to demonstrate allosteric regulation as p53 target
promoters do not exhibit signiﬁcant enrichment in p53
binding after genotoxic stress (13).
Instead, some recent studies have worked out a positive
regulatory role of the CTD (14,15): McKinney et al. have
demonstrated the involvement of the CTD in the ability of
p53 to diﬀuse linearly on DNA, a concept supported by
previous time-lapse atomic force microscopy studies
(14,16). Based on these ﬁndings, a sliding (or facilitated
search) model has been postulated proposing that p53
binds to the genomic DNA in a sequence-nonspeciﬁc
manner via its CTD. It slides along the DNA searching for
p53 response elements which are ultimately bound in a
sequence-speciﬁc manner via the core domain. The CTD
would thus facilitate the search for speciﬁc targets in the
context of a complex genome. Consistently, the CTD is
required for eﬃcient promoter activation in vivo early after
protein induction when p53 protein levels are limiting
(14,15). At later time points or at higher expression
levels the favorable role of the CTD became negligible
(17,18).
In 1997 the cloning of p73 as a second p53 family
member was reported and rapidly followed by the
discovery of p63 as the third member (19–22). The overall
protein architecture is highly conserved among the three
family members and the highest degree of sequence
homology is seen within the DNA binding core domain.
p63 and p73 share  65% amino acid identity with the core
domain of p53, and even higher identity with each other
(1). Despite this structural homology the proteins have
fundamentally diﬀerent functions in vivo as indicated by
the analysis of knockout mice (23–26): whereas tumor
susceptibility is the primary phenotype of the p53 knock-
out (26,27), p63 and p73 knockouts are both characterized
by severe developmental abnormalities and only moder-
ately enhanced tumor incidence (28).
All three genes express a multitude of diﬀerently spliced
isoforms—a feature that was thought to be unique for p63
and p73 but has recently been shown to also be true for
p53 (29). Most of the alternative splicing occurs at the 30
end, involves exons 10 to 13, and generates transcripts
encoding protein isoforms with diﬀerent CTDs as depicted
in Figure 1 for p73. Whereas the full-length protein
appears to be the predominant p53 isoform, at least two
diﬀerently spliced isoforms with diﬀerent C-terminal
sequences are commonly expressed in the case of p63
(p63a and p63g) and p73 (p73a and p73b). A number of
other splice variants (e.g. p73g and p73d) have been
reported, however, their physiological functions still
remain to be elucidated (30,31). From overexpression
studies it is known that the various p73 isoforms have very
diﬀerent transactivation potential indicating crucial func-
tions of the CTDs in transactivation control (30,32–36).
Considering the role of the p53 CTD in linear diﬀusion
we here investigated the function of the p73 CTD in
comparison to p53. We show that the electrostatic charge
of the CTDs of the various p53 family proteins diﬀers
signiﬁcantly and correlates inversely with DNA binding
in vitro and in vivo. p53 and p73g which both have a basic,
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Figure 1. C-terminal charge of p53 and p73 isoforms. Shown are the domain structure and C-terminal charge distribution of p53, the p73 isoforms
p73a, b, g and d, the CTD-deleted p5330 and the p53/p73 chimera p73a+30. C-terminal regions in p73b, g and d that diﬀer from the sequence in
p73a are shaded in dark grey. The percentage of conserved residues in the transactivation (TA), DNA binding core (DBD) and oligomerization (OD)
domain of p53 and p73 is shown. The calculated isoelectric points (pI values) of the total protein, the C-terminus (CT) and the last 30 amino acids
are shown in the table for each protein. In the case of p73, CT is deﬁned as the sequence C-terminal to the conserved oligomerization domain.
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protein–DNA complexes. In contrast, most p73 isoforms
(a, b and d) have neutral C-terminal sequences and bind
DNA strongly. Importantly, the DNA-binding properties
observed in vitro directly correlate with promoter binding
and target gene activation in vivo. Adding the basic p53
CTD to the p73a C-terminus inhibits p73 DNA binding
in vitro and reduces the transcriptional activity in vivo.
Together with the previously proposed facilitated search
model our results indicate that the basic p53 CTD
represents an autonomous, transposable domain that
provides both positive and negative regulatory functions
presumably to enable rapid switching of protein activity in
response to stress. The major p73 isoforms p73a and p73b
lack this functional domain consistent with their pre-
dominant role in developmental control. CTD diversity
within the p53 family therefore provides an additional
layer of complexity useful to ﬁne-tune cell fate decisions
that are regulated by the p53 family.
MATERIALS AND METHODS
Celllines and cell culture
H1299, Saos-2 and 293 cells were cultured in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM, Sigma) supplemented
with 10% fetal bovine serum (Sigma), 1% penicillin/
streptomycin (Sigma) and 0.4% amphotericin B (Sigma).
Transfections were performed using Escort V reagent
(Sigma) according to the manufacturer’s instructions.
Adenoviruses were produced using the AdEasy system
(37) and ampliﬁed on 293 cells.
Plasmids
Expression vectors for HA-tagged p53, p73a, p73b, p73g
and p73d have been described (30,38). cDNAs for p53,
p5330 (amino acids 1–363 of human p53), p73a and
p73a+30 (amino acids 364–393 of p53 fused to the
C-terminus of p73a) were generated by PCR using
pCMV-p53wt (39) and pcDNA3-HA-p73a (30) as tem-
plates. The primers used are as follows: p53-F: 50-CAC
CAT GGA GGA GCC GCA GTC A-30, p53-R: 50-TCA
GTC TGA GTC AGG CCC TTC-30, p5330-R: 50-TCA
CCT GCT CCC CCC TGG CTC-30, p73a-F: 50-CAC
CAT GGC CCA GTC CAC CGC C-30, p73a-R: 50-TCA
GTG GAT CTC GGC CTC CGT-30, p73a+30-A:
50-CGA GAT CCA CGC TCA CTC CAG CCA CCT
GAA G-30, p73a+30-B: 50-TGG AGT GAG CGT GGA
TCT CGG CCT CCG TGA A-30. pENTR-p53/p5330/
p73a/p73a+30 plasmids were generated by topo-ligation
of the gel-puriﬁed PCR products into pENTR/D-Topo
(Invitrogen). Expression vectors for in vitro translation
were generated by LR-recombination of pENTR vectors
with pEXP1/DEST vectors leading to the expression
of His-tagged proteins using the Gateway system
(Invitrogen).
pAdTrack-HA-p53/p5330/p73a/p73a+30 vectors
were generated by in vitro recombination of Gateway-
adapted pAdTrack-CMV-HA with respective pENTR
vectors using the Gateway system (Invitrogen).
pAdGFP-HA-p53/p5330/p73a/p73a+30weregenerated
by bacterial recombination using the AdEasy system as
described (37).
To generate YFP fusion proteins of p53, p5330, p73a
and p73a+30, the coding sequence of EYFP (Clontech)
was cloned into XbaI and PacI sites of pUC19-SﬁI/T7
(kindly provided by Rob Chapman). In addition, the
respective p53/p73 cDNA were cloned into XhoI and
XbaI sites and an HA-Flag-tag into AgeI and SpeI sites of
pUC19-SﬁI/T7. The complete resulting coding sequence
was excised with SﬁI and cloned into the episomal
doxycycline-inducible expression vector pRTS-1 (40).
Electrophoretic mobility shiftassay(EMSA)
EMSAs were performed in 20ml mixtures containing
20mM HEPES (pH 7.8), 0.5mM EDTA (pH 8.0), 6mM
MgCl2, 60mM KCl, 1mM DTT, 120ng sheared salmon
sperm DNA, 0.1 pmol of
32P end-labeled oligonucleotide,
and 1–5ml of the in vitro translated protein (TNT Quick
Coupled Transcription/Translation Set; Promega). For
supershift analysis 0.2mg a-HA (Y-11, Santa Cruz)
or a-His (Qiagen) antibody were added. The p53 CTD
was blocked by addition of 0.2mg a-p53 (PAb421,
Calbiochem) antibody. For competition experiments a
200-fold molar excess of self-competitor (oligonucleotide
with the same sequence as the labeled probe without the
32P labels) or unspeciﬁc competitor (unlabeled oligonu-
cleotide with a scrambled sequence) were used. After
30min incubation at room temperature, reaction mixtures
were subjected to electrophoresis on a 3.5% native
polyacrylamide gel (37.5:1 acrylamide/bisacrylamide) con-
taining 0.5  Tris–borate–EDTA buﬀer at 150V for
120min at room temperature. DNA protein complexes
were visualized by phosphorimaging (FLA-3000,
Fujiﬁlm). For quantiﬁcation, phosphor-stimulated lumi-
nescence (PSL) values were background corrected and
normalized to the sum of the bound and unbound
oligonucleotide signals.
The following double-stranded oligonucleotides (p53-
binding sites underlined) were used for EMSAs: p53
consensus sequence 50-GGG TAG ACA TGC CTA GAC
ATG CCT AAG CTC CC-30, p53 consensus scrambled 50-
GGG CCA GCT AGC AGG CAG CAT CAG TAC TTC
CC-30, p21-50 site (28bp) 50-TCA GGA ACA TGT CCC
AAC ATG TTG AGC T-30, p21-50 site (66bp) 50-AGC
ATT GGC TTT CTG GCC ATC AGG AAC ATG TCC
CAA CAT GTT GAG CTC TGG CAT AGA AGA GGC
GCT-30.
Protein analysis
The isoelectric points of the total protein, the C-terminal
region (CT) and the last 30 amino acids were calculated
with VectorNTI software (Invitrogen). Cells were lysed in
RIPA buﬀer (50mM Tris–Cl, 150mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS) and total protein
concentration was quantiﬁed by Bradford assay. Cell
lysates or in vitro translated protein samples were
separated by SDS–PAGE and transferred to nitrocellulose
membranes (Amersham). After blocking with 10% nonfat
dry milk, membranes were probed with antibodies speciﬁc
for the His-tag (Qiagen), HA-tag (Y-11, SantaCruz)
1902 Nucleic Acids Research, 2008, Vol. 36, No. 6or b-actin (AC15, Abcam) and visualized using appro-
priate horseradish-peroxidase-conjugated secondary anti-
bodies according to the enhanced chemiluminescence
protocol.
Fluorescence recovery after photobleaching (FRAP)
Cells were seeded onto gelatine-coated coverslips, trans-
fected with Tet-inducible expression vectors for p53,
p5330, p73a or p73a+30 as indicated and treated with
1mg/ml doxycycline. Twenty-four hours post transfection,
coverslips were transferred to a live-cell imaging chamber
with DMEM without phenol red (PAN) supplemented
with 10% fetal bovine serum. Photobleaching experiments
were performed on a Leica TCS SP5 equipped with a
63/1.4NA oil immersion objective. YFP was excited using
the 514nm laser line of an argon ion laser and imaged with
a spectral detector with a bandpass set at 518–608nm.
A YFP ﬂuorescence image of the whole cell was captured
before and after the FRAP experiment to determine the
location of the nucleus and to determine the photobleach-
ing and recovery levels, including observations of immo-
bile fractions. The FRAP protocol was performed
similarly to the method of Hinow et al. (41). Brieﬂy, a
41.01 by 2.56mm strip selected from the cellular image that
sliced out a central region through the nucleus was imaged
20 times before bleaching with 1% laser power of the
514nm laser line. This strip was photobleached by a series
of bleach pulses for 1s using all of the argon ion laser
lines combined at maximum (100%) power. Recovery of
ﬂuorescence was measured for 20s with settings as before
bleach in intervals of 100, 250 and 500ms for 2, 3 and 15s
intervals, respectively.
Mean ﬂuorescence intensity values of the nuclear part
were analyzed for each time point with either the Leica
SP5 software (LASAF ‘Frap Wizard’, Leica) or with
ImageJ software (NIH). Background intensities (of each
time point) were subtracted from each image before
analysis. To allow direct comparison of individual FRAP
curves, raw data were normalized to the mean prebleach
intensity of each cell measurement. The recovery curves
were then analyzed in Matlab (MathWorks, USA) with
modiﬁed routines from Hinow et al. (41) to determine the
parameters of the extended binding or free diﬀusion
model. The percentage of immobile fraction is calculated
by comparing prebleach intensity with recovered inten-
sities. For the best average representation of the FRAP
data, the recovery curves were averaged from at least
16 cells from several measurements on diﬀerent days,
depicting, the mean ﬂuorescence intensity SE of the
normalized values. Each of the individual curves was also
tested for the extended binding model whose ﬁtting to the
model could be rejected by goodness of ﬁt parameters
suggested by Hinow et al. (41).
Chromatin immunoprecipitation
The ChIP assay was essentially performed as described
(42). Brieﬂy, H1299 cells infected with adenoviruses
AdGFP, AdGFP-HA-p53 or AdGFP-HA-p5330 were
ﬁxed with formaldehyde (ﬁnal concentration 1% v/v) in
the cell culture medium for 10min at room temperature.
Glycine was added to a ﬁnal concentration of 0.125M to
stop cross-linking. Fixed cells were washed twice with ice
cold PBS, scraped and pelleted by centrifugation. Cells
were resuspended in SDS lysis buﬀer (50mM Tris–HCl
pH 8.1, 10mM EDTA, 1% v/v SDS) including protease
inhibitors and soniﬁcated to yield chromatin fragments of
approximately 500–1000bp as assessed by agarose gel
electrophoresis. The cell lysates were diluted with ChIP
dilution buﬀer (167mM NaCl, 16.7mM Tris–HCl pH 8.1,
1.2mM EDTA, 1.1% v/v Triton X-100, 0.01% v/v SDS),
precleared by incubation with blocked protein G agarose
(Upstate) and incubated with 1mg of anti-HA (Y-11,
SantaCruz) or anti-largeT (Pab 101, Santa Cruz) anti-
bodies overnight at 48C. Samples of total chromatin were
taken at this point as input controls for the PCR reactions.
Blocked protein G agarose was added and DNA–protein
complexes were washed with low salt (150mM NaCl,
20mM Tris–HCl pH 8.1, 2mM EDTA, 1% v/v Triton X-
100, 0.1% v/v SDS), high salt (500mM NaCl, 20mM
Tris–HCl pH 8.1, 2mM EDTA, 1% v/v Triton X-100,
0.1% v/v SDS), LiCl immune complex wash buﬀer
(20mM Tris–HCl pH 8.1, 2mM EDTA, 1% v/v deoxy-
cholic acid, 1% v/v IGEPAL-CA630, 250mM LiCl) and
twice with TE buﬀer and ﬁnally eluted with two
incubations in elution buﬀer (1% v/v SDS, 0.1M
NaHCO3) at room temperature for 15min each. Cross-
links were reversed by incubation at 658C for 5h followed
by RNase A (378C, 30min) and proteinase K (458C, 2h)
treatment. Samples were extracted twice with phenol-
chloroform and ethanol precipitated overnight in the
presence of 20mg glycogen as carrier. Resuspended DNA
fragments were used for quantitative PCR with primers
for the GAPDH (50-GTA TTC CCC CAG GTT TAC
AT-30,5 0-TTC TGT CTT CCA CTC ACT CC-30) and the
50 p53-binding site in the p21 promoter (50-GTG GCT
CTG ATT GGC TTT CTG-30,5 0-CTG AAA ACA GGC
AGC CCA AG-30). ChIP data from triplicate measure-
ments were expressed as promoter occupancy in percent
of input DNA.
RNA isolation, reverse transcription PCR
RNA was isolated using the RNeasy Kit (Qiagen) and
quantiﬁed with RiboGreen (Molecular Probes). Total
RNA (1mg) was reverse transcribed using Omniscript RT
(Qiagen) with random hexamers or the QuantiTect
Reverse Transcription Kit (Qiagen). Speciﬁc cDNAs
were quantiﬁed by qPCR performed in triplicate reactions
on an ABI Prism 7000 Sequence Detection System
(Applied Biosystems) using the SYBR Green JumpStart
Taq ReadyMix (Sigma) or the QuantiTect SYBR Green
PCR Kit (Qiagen) in combination with QuantiTect Primer
Assays for GDF15, JAG2, FDXR, PUMA/BBC3 and
S100A2 (Qiagen). Primer sequences for p21: 50-TGG
AGA CTC TCA GGG TCG AAA-30,5 0-GGC GTT TGG
AGT GGT AGA AAT C-30, GAPDH: 50-AAT GGA
AAT CCC ATC ACC ATC T-30,5 0-CGC CCC ACT
TGA TTT TGG-30. Ampliﬁcation speciﬁcity was veriﬁed
by melting curve analysis and agarose gel electrophoresis
of the PCR products. Expression data were normalized to
Nucleic Acids Research, 2008, Vol. 36, No. 6 1903GAPDH and the GFP-infected control sample using the
Ct method.
Microarrays
H1299 cells were harvested 24h after infection with
adenovirus expressing GFP together with HA-tagged
p53/p5330/p73a/p73a+30 or GFP only to control for
eﬀects of adenoviral infection. Total RNA was extracted
as described above. Equal amounts of RNA were pooled
from three independent infections. The samples were
analyzed for gene expression using Aﬀymetrix GeneChip
Human Genome U133A 2.0 Arrays and further analyzed
with GeneSpring 7.0 (Silicon Genetics) to extract a list
of 191 genes that were changed >3-fold in any p53/p73
expressing sample compared to the GFP control. The
complete set of microarray data has been deposited
in NCBI’s Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/) and is accessible through
GEO Series accession number GSE8660.
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
fdojhkemwaiskvc&acc=GSE8660
Flow cytometry
H1299 or Saos-2 cells were collected 24h after infection,
ﬁxed in 70% ethanol and stained for DNA content with
propidium iodide (Sigma). Cell cycle proﬁles were
measured directly on a FACScalibur with Cellquest
software (Becton Dickinson). Cell cycle proﬁles were
analyzed with ModFit LT software (Becton Dickinson).
Statistical analysis
All numerical data are reported as the mean standard
deviation (SD) or standard error (SE) as indicated.
Statistical signiﬁcance was calculated using the two-sided
Student’s t-test.
RESULTS
C-terminal diversity of p53and p73 isoforms influences
sequence-specific DNA binding
Although p73 shares  65% amino acid identity with the
DNA binding domain of p53 and binds to the p53
consensus DNA sequence (43), the two proteins exhibit
fundamentally diﬀerent biological functions. To determine
whether diﬀerences are already present on the level of
DNA binding we performed electrophoretic mobility shift
assays (EMSAs) with in vitro translated proteins and a
32P-labeled 28-bp double-stranded oligonucleotide con-
taining the p53 consensus binding sequence. Consistent
with previous studies (44–46) we observed only weak p53
complexes (Figure 2A, lanes 2–5). In contrast, sequence-
speciﬁc p73a complexes were inherently strong
(Figure 2A, lanes 10–13), despite equal amounts of p53
and p73a (Figure 2B, left panel). The speciﬁcity of these
protein–DNA complexes was conﬁrmed by eﬃcient
competition with the same but not a scrambled unlabeled
oligonucleotide and by supershift of the complex upon
addition of a speciﬁc antibody. Importantly, p53 complex
intensity was increased substantially and reached the
intensity of the p73 complexes following pre-incubation
with the antibody PAb421 (Figure 2A, lanes 6–9). Since
this antibody binds to a C-terminal epitope and blocks the
p53 CTD, functional diﬀerences of the p53 and p73a
CTDs presumably account for the diﬀerent complex
intensities.
We therefore further examined other p73 isoforms that
diﬀer in their CTDs. p73b and p73d are C-terminally
truncated versions of p73a, whereas p73g is characterized
by a unique C-terminal stretch of 76 amino acids
(Figure 1). Similar to p73a, the smaller p73 isoforms
p73b and p73d formed strong sequence-speciﬁc DNA
complexes (Figure 2A, lanes 19–22, 28–31), whereas p73g,
although equally expressed (Figure 2B, right panel),
formed only weak complexes similar to p53 (Figure 2A,
lanes 24–27). Together, these data demonstrate that the
various p53 family proteins diﬀer substantially with
respect to sequence-speciﬁc DNA binding in vitro and
suggest that sequence-speciﬁc DNA binding is strongly
inﬂuenced by functionally diﬀerent CTDs.
Sliding properties explain differences in sequence-specific
DNA binding
The inhibitory eﬀect of the p53 CTD on sequence-speciﬁc
DNA binding has repeatedly been observed in classical
EMSA experiments (10,14,44–47) and has recently been
explained by the ability of the C-terminus to promote
linear diﬀusion (sliding) along the DNA via sequence-
nonspeciﬁc DNA interactions (14,15). In this model, p53
can either dissociate from its speciﬁc binding site where it
is tightly bound in a sequence-speciﬁc manner via its core
domain or it can slide oﬀ the ends of a DNA fragment via
weak nonspeciﬁc interactions mediated by the C-terminus.
In the context of short oligonucleotides, linear diﬀusion
is dominant and results in p53 rapidly sliding oﬀ the
ends, which destabilizes the protein–DNA complexes.
Increasing the length of the oligonucleotide or blocking
the oligonucleotide ends with streptavidin prevents sliding
oﬀ, eliminates this mode of complex dissociation and
enhances overall complex stability (14,15). To investigate
the role of linear diﬀusion for the observed diﬀerences in
p53/p73 DNA binding we analyzed the eﬀects of longer
oligonucleotides on complex stability.
First, we performed EMSAs with 28 and 66bp DNA
fragments containing the 50-binding site of the p21
promoter, a common target of p53 and p73. As expected,
p53 complex intensity increased with the 66bp DNA
(Figure 3A, lanes 3 and 4). In the presence of PAb421,
p53 complex intensity was even stronger but no longer
dependent on oligonucleotide length, indicating that the
negative impact of sliding on sequence-speciﬁc DNA
binding is partially abrogated in the context of the longer
DNA and completely disabled by blocking p53’s CTD
(Figure 3A, lanes 5 and 6, Figure 3B). Of note, the
p53–DNA complex with the 66bp oligonucleotide
migrated faster than the 28bp complex which might be
due to bending of the longer DNA or a diﬀerent complex
stoichiometry (Figure 3A, lanes 5 and 6). Nevertheless,
the p73a complex was completely independent of oligo-
nucleotide length, providing evidence that DNA binding
1904 Nucleic Acids Research, 2008, Vol. 36, No. 6of p73a is not inhibited by sliding (Figure 3A lanes 7 and
8, Figure 3B). In contrast, DNA binding of the p73
isoform p73g was stimulated by longer DNA (Figure 3C),
suggesting that the p73g C-terminus has sliding properties
similar to p53. Similarly, complex intensities of p53 and
p73g, but not p73a, were enhanced when the DNA ends
were blocked by streptavidin barriers (data not shown).
Together these experiments indicate that p53 and p73g but
not p73a/b/d are capable of sliding and that this accounts
for the observed diﬀerences in sequence-speciﬁc DNA
binding.
Sliding properties ofp53 family proteins correlate with
differences inC-terminal charge
Knowing that the p53C-terminus is a highly positively
charged, basic domain and that linear diﬀusion is largely
based on electrostatic interactions between a positively
charged protein domain and the negatively charged DNA
backbone (48), we calculated the isoelectric points (pI) of
the various p53 and p73C-termini (Figure 1). In contrast
to the p53 CTD, which has a basic isoelectric point
(pI 10.0), the C-termini of p73a, p73b and p73d have a
neutral pI between 5.52 and 7.92. The isoelectric point of
p73g is much higher than that of the other p73 isoforms in
respect to both the complete C-terminus (CT, pI 11.76)
and the last 30 amino-acids (pI 8.77) resulting in a
positively charged C-terminus. The calculated C-terminal
charges therefore directly correlate with the observed
DNA-binding properties and explain the diﬀerent sliding
abilities.
C-terminal charge influences sequence-specific DNA
bindingin vitro
To test the impact of sliding on sequence-speciﬁc DNA-
binding avoiding confounding eﬀects of diﬀerent protein
backbones, we generated a chimeric construct p73a+30
containing the positively charged C-terminal 30 amino
acids of p53 fused to the C-terminus of p73a. A deletion
mutant of p53 lacking the C-terminal domain (p5330)
had been previously described and was used as a control
(14). Deletion of p53’s CTD strongly enhanced DNA
binding whereas fusion of this domain to p73a reduced the
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Nucleic Acids Research, 2008, Vol. 36, No. 6 1905DNA binding of p73a (Figure 4A) although respective
protein levels were pairwise equal (Figure 4D). These
eﬀects were observed in the context of long 66bp
oligonucleotides (Figure 4A, right panel) and even more
pronounced with short 28bp oligonucleotides (Figure 4A,
left panel). Similar to p53, DNA binding of p73a+30 was
stimulated approximately 5-fold by long 66bp compared
to 28bp oligonucleotides (Figure 4B). The DNA-binding
activity of p73a+30 was restored to p73a levels upon pre-
incubation with PAb421, ruling out that the fusion-caused
misfolding of the p73 core DNA-binding domain
(Figure 4C). These data demonstrate that the positively
charged p53 CTD is an autonomous and transposable
domain that confers sliding properties and negatively
aﬀects the sequence-speciﬁc DNA-binding properties of
not only p53 but also when fused experimentally to p73.
p53CTD limits intranuclear mobility in vivo
Sequence-nonspeciﬁc interactions with chromatin and
linear diﬀusion along the DNA backbone are expected
to signiﬁcantly reduce the freedom in its motion. Hinow
et al. have recently shown by ﬂuorescence recovery after
photobleaching (FRAP) experiments that the intranuclear
mobility of p53 largely follows a sequence-nonspeciﬁc-
binding model which requires a binding region of the
protein apart from the DNA binding core domain (41).
We therefore used FRAP to determine whether a charged
CTD inﬂuences the mobility of p53 and p73 in the living
cell (Figure 5). For this p53, p5330, p73a and p73a+30
were fused to the yellow ﬂuorescent protein (YFP) and
transiently expressed in p53-null H1299 cells. All fusion
proteins were expressed to equal levels and localized
predominantly to the nucleus (Figure 5A). Photobleaching
was performed on a 2.56mm wide strip for 1s. Sequential
scanned images following photobleaching were utilized
to determine the kinetics of ﬂuorescence recovery
(Figure 5B). Freely diﬀusing YFP and the immobile
histone fusion protein H2B-YFP were also analyzed for
comparison showing a fast, nearly nondetectable bleach
and recovery for free YFP and a clearly deep bleach
without recovery for the histone. Bleaching depths for p53
and p73a were comparable and both recovered to similar
extent. Under equal bleaching conditions, the bleaching
was less and recovery was higher for p5330 compared to
p53. In contrast, the fusion of the p53 CTD to the p73a
C-terminus increased the bleaching and lowered the
recovery level. A reduced bleaching depth in comparison
to p53 as seen for p5330 indicates a higher mobility
similar to the free YFP and results from rapid recovery
during the bleaching period before the ﬁrst detected
recovery data point. A high bleaching depth as seen for
p73a+30 in comparison to p73a is typical for immobile
proteins like the chromatin component histone H2B.
As a further test, we applied the reaction-diﬀusion
model suggested by Hinow et al. (41) which includes
binding and release rates of the diﬀusing species to an
immobile structure on the individual recovery curves for
p53, p5330, p73a and p73a+30 to ﬁnd ﬁrst that the
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Figure 3. Enhanced binding of p53 and p73g but not p73a to longer DNA oligonucleotides. (A) EMSA showing binding of in vitro translated p53
and p73a to double-stranded
32P labeled oligonucleotides containing 28bp or 66bp from the 50 p53-binding site of the human p21 promoter. The p53
CTD was blocked by addition of 200ng anti-p53 (PAb421) antibody. Protein–DNA complexes were visualized and quantiﬁed by phosphorimaging.
(B) Graphical analysis of the phosphorimaging data depicted in (A). Binding was normalized to the 28bp oligonucleotide. Data represent the
mean SD of three independent EMSA experiments. RU, relative units. (C) DNA binding of in vitro translated p73g as described in (A). A 200-fold
excess of the same oligonucleotide without
32P label was used as a speciﬁc competitor, a scrambled sequence as an unspeciﬁc competitor.
1906 Nucleic Acids Research, 2008, Vol. 36, No. 6YFP fusion of p53 showed similar behavior as reported
for the GFP fusion to p53 (41). Second, in the case of
p5330 and p73a the ﬁt to the reaction-diﬀusion model
(Figure 5C, blue curves) provided no further improvement
compared to a one-parameter model involving only free
diﬀusion (Figure 5C, red curves), indicating no contribu-
tion of nonspeciﬁc DNA binding to intranuclear mobility
(Figure 5C). In summary, the proteins containing the basic
CTD were more similar to the immobile histone H2B,
whereas the proteins lacking a basic CTD were more
similar to free YFP. Thus we conclude that the charged
p53 CTD mediates sequence-nonspeciﬁc interactions with
genomic DNA in vivo.
p53 CTD inhibits p21promoter bindingin vivo
Considering that the ability to slide inhibits sequence-
speciﬁc DNA binding in vitro and intranuclear mobility
in vivo, we analyzed by chromatin immunoprecipitation
(ChIP) whether a similar negative impact can be observed
on gene expression in vivo. It has been previously shown
that the p53 CTD functions as a positive regulator of
DNA binding in vivo when p53 is exogenously expressed in
p53-null cells under conditions where the amount of p53
protein is limiting (14,15). Under these conditions scan-
ning of the genome by linear diﬀusion is expected to
enhance the identiﬁcation of p53-binding sites in the
complex genome. However, in p53-wild-type cells, p53 is
known to be present on target promoters like the p21
promoter under both stressed and unstressed conditions
so that the identiﬁcation of binding sites in the genome
should not be the rate-limiting step in the stress response
(13,49). To investigate if the p53 CTD inﬂuences promoter
binding under these conditions, we expressed p53 (or
p5330) in H1299 cells by means of adenoviral infection
and analyzed promoter binding 24h later when constantly
high steady-state levels of p53 were obtained.
ChIP analyses revealed enrichment of p21
CDKN1A
promoter DNA by both p53 and p5330 (Figure 6).
p73a and p73a+30 did not signiﬁcantly associate with the
p21 promoter (data not shown) consistent with the lack of
p21 transactivation under these conditions (Figure 7C).
Importantly, promoter binding was signiﬁcantly higher
for p5330 than for p53 (P=0.011). The speciﬁcity of
these results was conﬁrmed by the lack of binding to the
A
66 bp oligo
in vitro translation
28 bp oligo
free 66 bp oligo
p53 or p73
complexes
unspecific
complexes
free 28 bp oligo
5 3 14 2
− − −− −
+ + ++ +
p
5
3
p
5
3
∆
3
0
p
7
3
α
p
7
3
α
+
3
0
6
++ ++ +
9 78 1 0
−− −− −
-
p
5
3
p
5
3
∆
3
0
p
7
3
α
p
7
3
α
+
3
0
-
D
p
5
3
p
5
3
∆
3
0
p
7
3
α
p
7
3
α
+
3
0
100 kD
75 kD
C
in vitro translation
p73
complexes
PAb101
3 14 2
− − + −
-
p
7
3
α
p
7
3
α
+
3
0
p
7
3
α
+
3
0
PAb421 + −− − + − −
− + −
p
7
3
α
+
3
0
p
7
3
α
p
7
3
α
567
B
21 0 34567 9 8
−− ++++−− −
− + −−−+ −− −
−− −−+ −− + −
−− − + −−− − +
− + +++++ + + p73α+30
specific competitor
unspecific competitor
anti-HA
66 bp oligo
28 bp oligo
1
+
−
−
−
−
++ −−−−++ + −
free 66 bp oligo
p73α+30
complexes
unspecific
complexes
free 28 bp oligo
Figure 4. The p53 CTD is an autonomous transposable negative regulatory domain. (A, B) EMSA of the indicated in vitro translated proteins to
32P labeled oligonucleotides of the indicated size containing the 50 p53-binding site of the p21 promoter. A 200-fold molar excess of the same
oligonucleotide without
32P label was used as a speciﬁc competitor, a scrambled oligonucleotide as an unspeciﬁc competitor. A 200ng anti-HA
antibody was added for supershift analysis as indicated. (C) EMSA of p73 and p73+30 binding to the
32P labeled p53 consensus oligonucleotide.
The p53 CTD was blocked by addition of 200ng PAb421. PAb101 directed against the SV40 large T antigen was used as a control. (D) Western blot
demonstrating pairwise equal amounts of protein.
Nucleic Acids Research, 2008, Vol. 36, No. 6 1907promoter of the non-target gene GAPDH and by the
absence of a p21 promoter signal when using a nonspeciﬁc
antibody (Figure 6). We conclude that the positively
charged p53 CTD has a statistically signiﬁcant negative
regulatory impact on sequence-speciﬁc DNA binding not
only in vitro but also in vivo when the amount of p53
protein is not limiting.
p53CTD reduces transcriptional activity ofp53 and p73
As DNA binding of a transcription factor is a prerequisite
for transactivation, we next examined diﬀerences in
genome-wide gene expression proﬁles using unbiased
oligonucleotide microarrays. For this we isolated mRNA
of H1299 cells 24h after infection with adenoviruses
expressing pairwise equal amounts of p53 and p5330 or
p73a and p73a+30, respectively (Figure 7). mRNA from
three independent experiments was pooled to increase the
accuracy of the microarray results. 191 genes were
changed by more than 3-fold in at least one of the four
p53/p73-samples compared to the AdGFP-infected con-
trol (Figure 7A). Among these genes were several known
p53/p73 target genes involved in cell cycle regulation
(p21
CDKN1A), diﬀerentiation and development (S100A2,
GDF15, JAG2) and apoptosis (FDXR, PUMA/BBC3).
The heat map depicts that the target gene spectrum is
mainly determined by the protein backbone, i.e. despite
signiﬁcant overlap condition clustering clearly distin-
guished the p53-driven expression proﬁles from the p73
samples (Figure 7A). Deletion or addition of the p53 CTD
did not shift the target gene spectrum but rather changed
the level of target gene activation as was conﬁrmed by
quantitative RT-PCR (Figure 7C). p5330-transactivated
p53 target genes stronger than wildtype p53 whereas p73a-
transactivated p73 target genes better than p73a+30
(Figure 7C). Thus the absence of a positively charged
C-terminus in p5330 and p73a not only enhanced
promoter binding in vitro and in vivo but also resulted in
elevated gene transcription providing further support for a
negative regulatory role of a positively charged CTD.
C-terminal domaininfluences cell fate control
To determine whether the observed diﬀerences in DNA
binding and transactivation inﬂuence cell fate decisions,
we analyzed the induction of cell-cycle arrest and
apoptosis. Infection of H1299 cells with adenoviruses
expressing p53 or p5330 resulted in strong induction of
apoptosis compared to the GFP control cells (Figure 8A).
As previously seen on the level of target gene expression,
the eﬀect of p5330 on apoptosis induction was clearly
enhanced compared to wild-type p53. p73a and p73a+30
did not increase the apoptosis rate in H1299 cells, but
reduced the percentage of cells in S-phase similar to p53.
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Figure 5. Inﬂuence of p53 CTD on intranuclear mobility. (A) Fluorescence micrographs of H1299 cells transfected to express YFP fusion proteins
of p53, p5330, p73 and p73+30. Scale bar, 10mm. (B) Fluorescence recovery after photobleaching (FRAP). H1299 cells were transfected with YFP
fusion proteins. Shown are ﬂuorescence recovery curves calculated from sequential scanned images recorded after photobleaching of a 2.56mm
wide strip for 1s. Examples of the bleached areas are shown in (A). Fluorescence intensity before photobleaching was set to 100%. Each data point
represents the mean SE of n cells. Recovery curves of immobile histone H2B and highly mobile free YFP are shown for comparison.
(C) Representative FRAP data from individual cells ﬁtted to the free-diﬀusion model (red curves) and the extended reaction-diﬀusion model (blue
curves) according to Hinow et al. (41). P value, conﬁdence level of improvement by the extended model.
1908 Nucleic Acids Research, 2008, Vol. 36, No. 6Again p73a was more eﬀective than p73a+30. The nega-
tive impact of the charged p53 CTD on the ability of p53
and p73 to regulate cell cycle progression and apoptosis
was further conﬁrmed in Saos-2 cells as a second p53-null
cell line (Figure 8B and C). We conclude that a positively
charged CTD reduces the anti-proliferative activity of p53
family members. The implications of these ﬁndings are
discussed below.
DISCUSSION
In this study we show that the CTDs of p53 and various
p73 isoforms diﬀer in their electrostatic charge and
therefore in their ability to interact with DNA in a
sequence-nonspeciﬁc manner. Although the p53 CTD has
long been known to be an independent DNA-binding
module (5,17), our results demonstrate that a functionally
equivalent domain is missing in the major p73 isoforms
(with the exception of p73g). In the case of p53,
interactions of the CTD with DNA compromise the
stability of sequence-speciﬁc complexes with short oligo-
nucleotides which is elegantly explained by the recently
proposed p53 sliding model (5,17). In the context of short
DNA, CTD-mediated linear diﬀusion results in rapid
sliding oﬀ the DNA ends and thus dissociation of the
protein–DNA complex. Consistently, all experimental
measures that interfere with this process such as blocking
the DNA ends with streptavidin (14), ligating the DNA
Figure 7. The p53 CTD reduces transactivation of target genes. (A)
Gene expression proﬁles of H1299 cells infected with adenoviruses
expressing GFP alone or in combination with p53, p5330, p73a or
p73a+30. Samples from three independent infections were pooled for
microarray analysis using Aﬀymetrix Human Genome U133A 2.0
Arrays. Shown is a heatmap of the 191 genes that were changed by
more than 3-fold in at least one of the four p53/p73 samples compared
to the GFP control. (B) Western blot demonstrating pairwise equal
expression of p53 and p73 proteins following infection of H1299 cells
with the indicated adenoviruses. b-actin expression is shown as a
loading control. (C) Quantitative RT-PCR of the samples in (A) for
expression of p53 target genes (GFP15, p21, JAG2, PUMA/BBC3,
FDXR) and the p73 target gene S100A2. Shown is the mean fold
induction SD of three replicate measurements.
Figure 6. Deletion of the p53 CTD enhances in vivo binding to the p21
promoter. ChIP (chromatin immunoprecipitation assay) comparing
in vivo binding of p53 and p5330 to the 50 p53-binding site in the p21
promoter. Binding to a region within the GAPDH promoter is shown
as a negative control. Binding to the p21 promoter of a control
immunoprecipitation using an antibody directed against large T antigen
(LT) is shown as an additional negative control. ChIP data were
quantitated by qPCR and normalized to their respective inputs for p21
and GAPDH. The graph shows the mean and SD of promoter
occupancy in percent of input DNA (n=3). p21 promoter occupancy of
p53 and p5330 were signiﬁcantly diﬀerent (P=0.011). Protein levels
of p53 and p5330 are shown in Figure 7B.
Nucleic Acids Research, 2008, Vol. 36, No. 6 1909into circles (50), increasing the length of the DNA (12) or
blocking the CTD with antibodies (10) have been shown
to increase complex stability. As p73a, b and d have no
positively charged domain in their CTD they cannot
engage in sequence-nonspeciﬁc electrostatic interactions
with the negatively charged DNA backbone. Thus, their
binding is not aﬀected by any of the measures described
above. Direct dissociation is rare because of strong
sequence-speciﬁc protein–DNA interactions resulting in
very stable p73–DNA complexes. In fact, p73a, b and d
formed equally strong complexes as p53 proteins in which
the CTD had been blocked (Figure 2A) or deleted
(Figure 4A). This high p73–DNA complex intensity has
previously been observed in one of the ﬁrst EMSAs to be
reported for p73 (51). In contrast, no signiﬁcant diﬀerence
in DNA-binding strength was observed by Lokshin et al.
(52). This might be explained by the use of short
oligonucleotides as competitor DNA or recombinant
proteins expressed in insect cells which show diﬀerent
post-translational modiﬁcations compared to p53/p73
proteins produced by in vitro translation using mamma-
lian cell lysates (53).
In a living cell a second sequence-nonspeciﬁc DNA-
binding domain would be expected to enhance chromatin
association and therefore to reduce the freedom in its
motion. In fact, Hinow et al. demonstrated that the
intranuclear mobility of p53 is independent of its
sequence-speciﬁc DNA-binding properties and largely
determined by nonspeciﬁc binding to genomic DNA
(41). Consistent with the CTD harboring the sequence-
nonspeciﬁc DNA-binding function, we observed a change
in intranuclear mobility when the CTD was altered
(Figure 5). Deletion of the CTD increased the intranuclear
mobility of p53, whereas addition of the p53 CTD to the
p73a C-terminus reduced p73 mobility. This change in
intranuclear mobility cannot simply be explained by the
change in size which is only 30 amino acids and negligible
compared to the total size of the protein as recently shown
by small angle X-ray scattering (54). The intranuclear
mobility therefore inversely correlates with the predicted
degree of chromatin association indicating that protein–
DNA interactions as determined in vitro are similarly
observed in the living cell.
As expected from the negative regulatory role of
the p53 CTD in DNA-binding experiments, our study
demonstrates that the charged p53 CTD has a negative
impact on p21 promoter binding and gene transcription
on a genome-wide scale (Figures 6 and 7). These ﬁndings
are in contrast to recent reports which demonstrated
CTD-mediated sliding to enhance promoter binding and
gene transcription (14,17). A possible explanation for this
discrepancy could be based on the diﬀerent time points
and expression levels that were investigated. In contrast to
focusing on the initial steps of promoter localization
occurring when p53 is expressed at limited amounts in a
p53-null cell, we analyzed transcription 24h after the onset
of p53 expression when p53 levels were constant and no
longer limiting. We chose this late time point because
endogenous p53 is bound to its target promoters in
unstressed cells (13,49), so that the locating of p53-binding
sites in the genome might not be the rate-limiting step of
a p53-driven transcriptional stress response. It can be
envisioned that instead of promoting the search for p53
response elements, sliding enhances the dissociation of
promoter-bound p53 under steady-state conditions similar
as observed in EMSAs and thus reduces gene transcription
(Figure 9). Following initial steps where sliding is
beneﬁcial, sliding would therefore need to be turned oﬀ
once a response element has been identiﬁed to stabilize the
promoter-bound transactivation complex. This could be
accomplished in vivo by kinases or acetylases that are
known to reduce the C-terminal charge in response to
stress signals (55).
Another important aspect revealed by our study is
that the target gene spectrum is solely determined by
the identity of the DNA-binding domain. Despite over-
lapping target genes, the p53 target gene proﬁle can
be distinguished clearly from the p73-initiated transcrip-
tional response (Figure 7). Although molecules without
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Figure 8. The p53 CTD inhibits the p53/p73 response. (A) H1299 cells
were infected with adenoviruses expressing GFP alone or in combina-
tion with p53, p5330, p73a or p73a+30. Protein levels obtained by
adenoviral infection are shown in Figure 7B. Shown are the cell cycle
proﬁles measured 24h after infection. (B, C) Quantitative analysis of
(B) apoptosis (sub-G1) and (C) S-phase 24h after Saos-2 cells were
infected and analyzed as described in (A). The observed diﬀerences are
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1910 Nucleic Acids Research, 2008, Vol. 36, No. 6a charged CTD show increased transcriptional activity,
swapping CTDs does not switch the target gene spectrum.
p21 is predominantly activated by p53 and p5330,
whereas S100A2 is only activated signiﬁcantly by p73a
and p73a+30. This is consistent with the model, that the
CTD enhances dissociation of the protein–DNA complex
by enabling sliding oﬀ without directly inﬂuencing the
molecular interactions between the DNA-binding core
domain and the response element that determine sequence
speciﬁcity.
In contrast to p73a, b and d, p73g is characterized by a
basic CTD that allows for sequence-nonspeciﬁc DNA
binding. With respect to its DNA-binding properties p73g
is therefore the p73 isoform most similar to p53 and
indeed was more similar to p53 than to p73a in all DNA
binding assays. Unfortunately, very little is known about
the expression pattern and physiological role of p73g
possibly due to the absence of validated antibodies that
are speciﬁc for this isoform (30). Based on our results we
would predict p73g to be a latent protein similar to p53
that requires activation for full function. In line with this,
it has been shown that p73g cannot bind to p53 response
elements in vitro unless acetylated by PCAF (56).
Considering the diﬀerent phenotype of p53 and p73 loss
in mice, it is tempting to speculate that p73, which is
involved primarily in developmental control, does not
require rapid activity switching and therefore comes as a
transcriptionally regulated protein with constitutive
DNA-binding activity, whereas p53 and p73g are
endowed with a second regulatory DNA-binding domain
that keeps the proteins functionally latent but primed for
rapid activation in response to stress.
ACKNOWLEDGEMENTS
This work was funded by grants from the Deutsche
Forschungsgemeinschaft (Transregio TR17 ‘Ras-
dependent pathways in human cancer’, Forschungszen-
trum FZ82). A.R. is supported by the Interdisciplinary
Center for Clinical Research (IZKF), University of
Wu ¨ rzburg. We are grateful to Gerry Melino, Bert
Vogelstein and Georg Bornkamm for providing plasmids,
and Geoﬀrey Lambright and Mike Friedrich for their
assistance with FRAP experiments. Funding to pay the
Open Access publication charges for this article was
provided by the Deutsche Forschungsgemeinschaft.
Conﬂict of interest statement. None declared.
REFERENCES
1. Stiewe,T. (2007) The p53 family in diﬀerentiation and tumorigen-
esis. Nat. Rev. Cancer, 7, 165–168.
2. Vousden,K.H. and Lane,D.P. (2007) p53 in health and disease.
Nat. Rev. Mol. Cell. Biol., 8, 275–283.
3. Vogelstein,B., Lane,D. and Levine,A.J. (2000) Surﬁng the p53
network. Nature, 408, 307–310.
4. Kim,E. and Deppert,W. (2006) The versatile interactions of p53
with DNA: when ﬂexibility serves speciﬁcity. Cell Death Diﬀer., 13,
885–889.
5. Laptenko,O. and Prives,C. (2006) Transcriptional regulation by
p53: one protein, many possibilities. Cell Death Diﬀer., 13, 951–961.
6. Wang,Y. and Prives,C. (1995) Increased and altered DNA binding
of human p53 by S and G2/M but not G1 cyclin-dependent kinases.
Nature, 376, 88–91.
7. Takenaka,I., Morin,F., Seizinger,B.R. and Kley,N. (1995)
Regulation of the sequence-speciﬁc DNA binding function of p53
by protein kinase C and protein phosphatases. J. Biol. Chem., 270,
5405–5411.
8. Sakaguchi,K., Herrera,J.E., Saito,S., Miki,T., Bustin,M.,
Vassilev,A., Anderson,C.W. and Appella,E. (1998) DNA damage
activates p53 through a phosphorylation-acetylation cascade. Genes
Dev., 12, 2831–2841.
9. Gu,W. and Roeder,R.G. (1997) Activation of p53 sequence-speciﬁc
DNA binding by acetylation of the p53C-terminal domain. Cell, 90,
595–606.
10. Hupp,T.R., Meek,D.W., Midgley,C.A. and Lane,D.P. (1992)
Regulation of the speciﬁc DNA binding function of p53. Cell, 71,
875–886.
11. Ayed,A., Mulder,F.A., Yi,G.S., Lu,Y., Kay,L.E. and
Arrowsmith,C.H. (2001) Latent and active p53 are identical in
conformation. Nat. Struct. Biol., 8, 756–760.
12. Espinosa,J.M. and Emerson,B.M. (2001) Transcriptional regulation
by p53 through intrinsic DNA/chromatin binding and site-directed
cofactor recruitment. Mol. Cell, 8, 57–69.
13. Kaeser,M.D. and Iggo,R.D. (2002) Chromatin immunoprecipitation
analysis fails to support the latency model for regulation of p53
DNA binding activity in vivo. Proc. Natl Acad. Sci. USA, 99,
95–100.
14. McKinney,K., Mattia,M., Gottifredi,V. and Prives,C. (2004) p53
linear diﬀusion along DNA requires its C terminus. Mol. Cell, 16,
413–424.
15. Liu,Y., Lagowski,J.P., Vanderbeek,G.E. and Kulesz-Martin,M.F.
(2004) Facilitated search for speciﬁc genomic targets by
p53C-terminal basic DNA binding domain. Cancer Biol. Ther., 3,
1102–1108.
16. Jiao,Y., Cherny,D.I., Heim,G., Jovin,T.M. and Schaﬀer,T.E. (2001)
Dynamic interactions of p53 with DNA in solution by time-lapse
atomic force microscopy. J. Mol. Biol., 314, 233–243.
17. Liu,Y. and Kulesz-Martin,M.F. (2006) Sliding into home: facilitated
p53 search for targets by the basic DNA binding domain. Cell
Death Diﬀer., 13, 881–884.
CTD
DBD
p53
p73γ, p73α+30
p73α, β, δ
p53∆30
PTMs
PAb421
RE RE
sliding
off
sliding
direct
dissociation
from RE
direct
dissociation
from RE
dissociation
from
non-specific
DNA
Figure 9. Model. Transcription factor binding sites in the genome are
not only located and occupied but also left either directly via
dissociation or indirectly via sliding. In the case of p53, p73g and
p73a+30a charged CTD allows sequence-nonspeciﬁc interactions with
the DNA, enables sliding and thus destabilizes the sequence-speciﬁc
protein–DNA complex. In the case of p73a, p73b, p73d and p5330
these destablizing sequence-nonspeciﬁc interactions are absent so that
stable protein–DNA complexes are formed. Blocking the DNA binding
function of a basic CTD by antibodies (PAb421) in vitro or charge-
neutralizing post-translational modiﬁcations (PTM) in vivo stabilizes
promoter-bound complexes by preventing sliding oﬀ the binding site.
Sequence-nonspeciﬁc interactions therefore not only help to identify
response elements (RE) in the genome but also enable transcription
factors to leave these sites and therefore render these DNA-binding
activities a target for regulation.
Nucleic Acids Research, 2008, Vol. 36, No. 6 191118. Crook,T., Marston,N.J., Sara,E.A. and Vousden,K.H. (1994)
Transcriptional activation by p53 correlates with suppression of
growth but not transformation. Cell, 79, 817–827.
19. Osada,M., Ohba,M., Kawahara,C., Ishioka,C., Kanamaru,R.,
Katoh,I., Ikawa,Y., Nimura,Y., Nakagawara,A., Obinata,M. et al.
(1998) Cloning and functional analysis of human p51, which
structurally and functionally resembles p53. Nat. Med., 4, 839–843.
20. Schmale,H. and Bamberger,C. (1997) A novel protein with strong
homology to the tumor suppressor p53. Oncogene, 15, 1363–1367.
21. Yang,A., Kaghad,M., Wang,Y., Gillett,E., Fleming,M.D.,
Dotsch,V., Andrews,N.C., Caput,D. and McKeon,F. (1998) p63,
a p53 homolog at 3q27-29, encodes multiple products with
transactivating, death-inducing, and dominant-negative activities.
Mol. Cell, 2, 305–316.
22. Kaghad,M., Bonnet,H., Yang,A., Creancier,L., Biscan,J.C.,
Valent,A., Minty,A., Chalon,P., Lelias,J.M., Dumont,X. et al.
(1997) Monoallelically expressed gene related to p53at 1p36, a
region frequently deleted in neuroblastoma and other human
cancers. Cell, 90, 809–819.
23. Mills,A.A., Zheng,B., Wang,X.J., Vogel,H., Roop,D.R. and
Bradley,A. (1999) p63 is a p53 homologue required for limb and
epidermal morphogenesis. Nature, 398, 708–713.
24. Yang,A., Walker,N., Bronson,R., Kaghad,M., Oosterwegel,M.,
Bonnin,J., Vagner,C., Bonnet,H., Dikkes,P., Sharpe,A. et al. (2000)
p73-deﬁcient mice have neurological, pheromonal and inﬂammatory
defects but lack spontaneous tumours. Nature, 404, 99–103.
25. Yang,A., Schweitzer,R., Sun,D., Kaghad,M., Walker,N.,
Bronson,R.T., Tabin,C., Sharpe,A., Caput,D., Crum,C. et al. (1999)
p63 is essential for regenerative proliferation in limb, craniofacial
and epithelial development. Nature, 398, 714–718.
26. Donehower,L.A., Harvey,M., Slagle,B.L., McArthur,M.J.,
Montgomery,C.A.Jr, Butel,J.S. and Bradley,A. (1992) Mice
deﬁcient for p53 are developmentally normal but susceptible to
spontaneous tumours. Nature, 356, 215–221.
27. Harvey,M., McArthur,M.J., Montgomery,C.A.Jr, Butel,J.S.,
Bradley,A. and Donehower,L.A. (1993) Spontaneous and
carcinogen-induced tumorigenesis in p53-deﬁcient mice. Nat. Genet.,
5, 225–229.
28. Flores,E.R., Sengupta,S., Miller,J.B., Newman,J.J., Bronson,R.,
Crowley,D., Yang,A., McKeon,F. and Jacks,T. (2005) Tumor
predisposition in mice mutant for p63 and p73: evidence for broader
tumor suppressor functions for the p53 family. Cancer Cell, 7,
363–373.
29. Bourdon,J.C., Fernandes,K., Murray-Zmijewski,F., Liu,G.,
Diot,A., Xirodimas,D.P., Saville,M.K. and Lane,D.P. (2005) p53
isoforms can regulate p53 transcriptional activity. Genes Dev., 19,
2122–2137.
30. De Laurenzi,V., Costanzo,A., Barcaroli,D., Terrinoni,A., Falco,M.,
Annicchiarico-Petruzzelli,M., Levrero,M. and Melino,G. (1998)
Two new p73 splice variants, gamma and delta, with diﬀerent
transcriptional activity. J. Exp. Med., 188, 1763–1768.
31. De Laurenzi,V.D., Catani,M.V., Terrinoni,A., Corazzari,M.,
Melino,G., Costanzo,A., Levrero,M. and Knight,R.A. (1999)
Additional complexity in p73: induction by mitogens in lymphoid
cells and identiﬁcation of two new splicing variants epsilon and
zeta. Cell Death Diﬀer., 6, 389–390.
32. Zhu,J., Jiang,J., Zhou,W. and Chen,X. (1998) The potential tumor
suppressor p73 diﬀerentially regulates cellular p53 target genes.
Cancer Res., 58, 5061–5065.
33. Yu,J., Zhang,L., Hwang,P.M., Rago,C., Kinzler,K.W. and
Vogelstein,B. (1999) Identiﬁcation and classiﬁcation of
p53-regulated genes. Proc. Natl Acad. Sci. USA, 96,
14517–14522.
34. Ozaki,T., Naka,M., Takada,N., Tada,M., Sakiyama,S. and
Nakagawara,A. (1999) Deletion of the COOH-terminal region of
p73alpha enhances both its transactivation function and
DNA-binding activity but inhibits induction of apoptosis in
mammalian cells. Cancer Res., 59, 5902–5907.
35. Ueda,Y., Hijikata,M., Takagi,S., Chiba,T. and Shimotohno,K.
(2001) Transcriptional activities of p73 splicing variants are
regulated by inter-variant association. Biochem. J., 356, 859–866.
36. Lee,C.W. and La Thangue,N.B. (1999) Promoter speciﬁcity and
stability control of the p53-related protein p73. Oncogene, 18,
4171–4181.
37. He,T.C., Zhou,S., da Costa,L.T., Yu,J., Kinzler,K.W. and
Vogelstein,B. (1998) A simpliﬁed system for generating recombinant
adenoviruses. Proc. Natl Acad. Sci. USA, 95, 2509–2514.
38. Stiewe,T., Theseling,C.C. and Putzer,B.M. (2002) Transactivation-
deﬁcient Delta TA-p73 inhibits p53 by direct competition for DNA
binding: implications for tumorigenesis. J. Biol. Chem., 277,
14177–14185.
39. Baker,S.J., Markowitz,S., Fearon,E.R., Willson,J.K. and
Vogelstein,B. (1990) Suppression of human colorectal carcinoma
cell growth by wild-type p53. Science, 249, 912–915.
40. Bornkamm,G.W., Berens,C., Kuklik-Roos,C., Bechet,J.M.,
Laux,G., Bachl,J., Korndoerfer,M., Schlee,M., Holzel,M.,
Malamoussi,A. et al. (2005) Stringent doxycycline-dependent
control of gene activities using an episomal one-vector system.
Nucleic Acids Res., 33, e137.
41. Hinow,P., Rogers,C.E., Barbieri,C.E., Pietenpol,J.A.,
Kenworthy,A.K. and DiBenedetto,E. (2006) The DNA binding
activity of p53 displays reaction-diﬀusion kinetics. Biophys. J., 91,
330–342.
42. Cam,H., Griesmann,H., Beitzinger,M., Hofmann,L.,
Beinoraviciute-Kellner,R., Sauer,M., Huttinger-Kirchhof,N.,
Oswald,C., Friedl,P., Gattenlohner,S. et al. (2006) p53 family
members in myogenic diﬀerentiation and rhabdomyosarcoma
development. Cancer Cell, 10, 281–293.
43. Jost,C.A., Marin,M.C. and Kaelin,W.G.Jr (1997) p73 is a simian
[correction of human] p53-related protein that can induce apoptosis.
Nature, 389, 191–194.
44. Hupp,T.R. and Lane,D.P. (1994) Allosteric activation of latent p53
tetramers. Curr. Biol., 4, 865–875.
45. Hupp,T.R. and Lane,D.P. (1994) Regulation of the cryptic
sequence-speciﬁc DNA-binding function of p53 by protein kinases.
Cold Spring Harb. Symp. Quant. Biol., 59, 195–206.
46. Delphin,C., Cahen,P., Lawrence,J.J. and Baudier,J. (1994)
Characterization of baculovirus recombinant wild-type p53.
Dimerization of p53 is required for high-aﬃnity DNA binding and
cysteine oxidation inhibits p53 DNA binding. Eur. J. Biochem., 223,
683–692.
47. Jayaraman,L., Moorthy,N.C., Murthy,K.G., Manley,J.L.,
Bustin,M. and Prives,C. (1998) High mobility group
protein-1 (HMG-1) is a unique activator of p53. Genes Dev., 12,
462–472.
48. Berg,O.G., Winter,R.B. and von Hippel,P.H. (1981)
Diﬀusion-driven mechanisms of protein translocation on nucleic
acids. 1. Models and theory. Biochemistry, 20, 6929–6948.
49. Espinosa,J.M., Verdun,R.E. and Emerson,B.M. (2003) p53
functions through stress- and promoter-speciﬁc recruitment of
transcription initiation components before and after DNA damage.
Mol. Cell, 12, 1015–1027.
50. McKinney,K. and Prives,C. (2002) Eﬃcient speciﬁc DNA binding
by p53 requires both its central and C-terminal domains as revealed
by studies with high-mobility group 1 protein. Mol. Cell. Biol., 22,
6797–6808.
51. Marin,M.C., Jost,C.A., Irwin,M.S., DeCaprio,J.A., Caput,D. and
Kaelin,W.G.Jr (1998) Viral oncoproteins discriminate
between p53 and the p53 homolog p73. Mol. Cell. Biol., 18,
6316–6324.
52. Lokshin,M., Li,Y., Gaiddon,C. and Prives,C. (2007) p53 and p73
display common and distinct requirements for sequence speciﬁc
binding to DNA. Nucleic Acids Res., 35, 340–352.
53. Warnock,L.J., Raines,S.A., Mee,T.R. and Milner,J. (2005) Role of
phosphorylation in p53 acetylation and PAb421 epitope recognition
in baculoviral and mammalian expressed proteins. FEBS J., 272,
1669–1675.
54. Tidow,H., Melero,R., Mylonas,E., Freund,S.M., Grossmann,J.G.,
Carazo,J.M., Svergun,D.I., Valle,M. and Fersht,A.R. (2007)
Quaternary structures of tumor suppressor p53 and a speciﬁc
p53-DNA complex. Proc. Natl Acad. Sci. USA, 104, 12324–12329.
55. Bode,A.M. and Dong,Z. (2004) Post-translational modiﬁcation of
p53 in tumorigenesis. Nat. Rev. Cancer, 4, 793–805.
56. Momii,Y., Izumi,H., Shiota,M., Onitsuka,T., Abe,T.,
Kobayashi,H., Miyamoto,N., Uchiumi,T. and Kohno,K.
(2007) p73gamma transactivates the p21 promoter through
preferential interaction with the p300/CBP-associated factor in
human prostate cancer cells. Oncol. Rep., 18, 411–416.
1912 Nucleic Acids Research, 2008, Vol. 36, No. 6